News Author: Erilyn Riley Publish date: December 15, 2015
Photo courtesy of ASH
ORLANDO, FL—Investigators have observed early fulminant hepatotoxicity in a subset of primarily younger chronic lymphocytic l...
News Author: Erilyn Riley Publish date: December 12, 2015
Photo courtesy of ASH
ORLANDO, FL—Investigators from the Group for Research on Adult Lymphoblastic Leukemia (GRAALL) recommend integrating rituxima...
News Author: Erilyn Riley Publish date: December 11, 2015
Photo courtesy of ASH
ORLANDO, FL—After almost 10 years, during which time no new drug for acute myeloid leukemia (AML) has been approved, results ...
News Author: Erilyn Riley Publish date: December 8, 2015
Photo courtesy of ASH
ORLANDO, FL—A study comparing subjective versus objective reporting of treatment compliance in patients with acute lymphoblas...
News Author: Erilyn Riley Publish date: November 6, 2015
NEW YORK—Targeting the cell cycle with cyclin-dependent kinase (CDK) inhibitors may be an effective strategy to treat lymphoma and myeloma, acco...
News Author: Erilyn Riley Publish date: November 3, 2015
NEW YORK—Despite an “unprecedented” single-agent response rate and progression-free survival (PFS) in previously treated mantle cell...
News Author: Erilyn Riley Publish date: November 1, 2015
showing Hodgkin lymphoma NEW YORK—Using a 3-pronged approach to reprogram the immune system—inhibition of critical pathways, activation of others, ...
News Author: Erilyn Riley Publish date: October 30, 2015
NEW YORK—Long-term follow-up of single-agent ibrutinib at the approved dose of 420 mg daily confirms that the Bruton’s tyrosine kinase inh...
News Author: Erilyn Riley Publish date: October 29, 2015
showing CLL
Image by Mary Ann Thompson
NEW YORK—Despite enormous advances in therapies for chronic lymphocytic leukemia (CLL) that target the B-ce...
News Author: Erilyn Riley Publish date: October 28, 2015
showing multiple myeloma
NEW YORK—Results of an open-label, phase 2, dose-escalation study of ibrutinib combined with low-dose dexamethasone sugges...
News Author: Erilyn Riley Publish date: October 6, 2015
among uninfected cells (blue)
Image by Benjamin
Chaigne-Delalande
NEW YORK—Type 2 Epstein-Barr virus (EBV) tumors, such as Hodgkin and non-Hodgki...
News Author: Erilyn Riley Publish date: October 6, 2015
Photo courtesy of Baylor
College of Medicine
NEW YORK—Researchers are creating virus-specific T cells (VST) to treat and prevent viral infections ...
News Author: Erilyn Riley Publish date: October 1, 2015
NEW YORK—Researchers have developed a pharmaceutical-grade, third-generation, CD19-specific antibody that reduced minimal residual disease (MRD) in pe...
News Author: Erilyn Riley Publish date: September 30, 2015
Photo courtesy of MDACC
NEW YORK—Researchers have used a nonviral approach to create chimeric antigen receptor (CAR) T cells and tested these cells...
News Author: Erilyn Riley Publish date: September 24, 2015
NEW YORK—Investigators have found that B cells may play a role in stimulating graft-versus-leukemia (GvL) responses in patients with acute myeloid leu...
